Scholars Central

Mini reviewPublished 2015

Belimumab: Present and future

Authors: CD Tripathi, Preeta Kaur Chugh

Journal of Autoimmune Disorders

Volume 1 · Issue 1 · Pages 5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Belimumab, a B lymphocyte stimulator (BLyS) inhibitor, recently approved for patients with active, autoantibody-positive systemic lupus erythematosus (SLE) has paved the way for newer drugs that could arrest the complex autoimmune process and reverse the disease pathology. However, there is a need to further delineate long term effects of belimumab on disease activity and progression in patients with lupus nephritis, pregnancy and paediatric populations. Here, we review the on-going clinical trials and registry studies of belimumab in different populations that could define its role in the SLE armamentarium.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Autoimmune Disorders.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Autoimmune Disorders
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “CD Tripathi”
  • BylineArticles whose byline prints “Preeta Kaur Chugh”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels